The company will explore opportunity to close facilities during second half of 2019. Source: BioSpace

The company announced the pricing of its initial public offering of 6,667,000 common shares at an initial public offering price of $15.00 per common share. Source: BioSpace

The cash will allow the company to hire scientists to conduct preclinical research into a potential treatment for DMD. Source: BioSpace

The updated data will be presented at the 2017 Society for Immunotherapy of Cancer Annual Meeting. Source: BioSpace

Nearly four months after issuing a voluntary recall of all lots of unexpired sterile drug products, Cantrell Drug Company has filed for bankruptcy. Source: BioSpace

Five Prime stock took a beating after it unintentionally released Phase Ia/Ib clinical trial of its CSF-1R antibody cabiralizumab with BMS' Opdivo (nivolumab). Source: BioSpace

Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101. Source: BioSpace

Kerrisdale believes that Prothena's lead drug NEOD001 will fail in its current Phase 2b and Phase 3 trials. Source: BioSpace

Exonics Therapeutics closed on a $40M Series A financing which was led by The Column Group. Source: BioSpace

The hearing will focus on the therapeutic potential and ethical issues of using CRISPR technology to alter human DNA. Source: BioSpace